Study Examines Inhibitor Risk in Non-severe Hemophilia A
Intensive treatment with factor VIII, the clotting protein missing or defective in patients with hemophilia A, is associated with…
Articles by Patricia Inácio, PhD
Advocates Can Try for Grants Ahead of Rare Disease Week on Capitol Hill
Ahead of this year’s Rare Disease Week on Capitol Hill, held virtually July 14–22, the EveryLife Foundation will…
Hemophilia B Patients in US Face Great Financial, Personal Burden
Severe hemophilia B patients receiving prophylactic, or preventive treatment with factor IX face a significant financial and personal burden,…
Quick Approval Given COVID Vaccines Raise Concerns, Rare Disease Patients Say
More than half of the people with rare diseases and their caregivers, asked in a survey, were undecided or less…
EveryLife Scholarship Fund Open Until May 7 for Adults With Rare Diseases in US
The EveryLife Foundation for Rare Diseases is accepting applications for a scholarship program that aims to help adults with a…
Parents, Lacking Information, Wary of Gene Therapies, UK Survey Finds
Parents of children with hemophilia in the U.K. are generally aware of gene therapy, but many lack both the…
Scientists Identify New Genetic Mutations Underlying Hemophilia A
Using a combination of genetic and functional approaches, scientists have identified new mutations in parts of the F8 gene…
Hemophilia Treatments Should Be Open to All, Regardless of Cost, ICER Told
The full range of hemophilia treatments should be made available to patients without consideration of cost or other barriers, leaders of…
Acupuncture Might Work Better Than TENS to Reduce Chronic Joint Pain
Acupuncture was found to be more effective for reducing chronic joint pain in hemophilia patients than transcutaneous…
Hemlibra Improves Quality of Life in Children With Hemophilia A, Data Show
Preventive treatment with Hemlibra (emicizumab) improves health-related quality of life (HQRoL) in children with hemophilia A who develop…